Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage

[1]  Sung-Chun Tang,et al.  Impact of cerebral small vessel disease burden and drug level at admission on direct oral anticoagulant associated intracerebral hemorrhage , 2023, European stroke journal.

[2]  Y. Yagita,et al.  Resumption of oral anticoagulation in patients with non-valvular atrial fibrillation after intracerebral hemorrhage: A sub-analysis of the PASTA registry study , 2023, Journal of the Neurological Sciences.

[3]  Yaodong Zhang,et al.  Comparison of early and delayed anticoagulation therapy after ischemic stroke in patients with atrial fibrillation: a systematic review and meta-analysis , 2023, Journal of Thrombosis and Thrombolysis.

[4]  M. Gooch,et al.  Resuming Anticoagulants in Patients With Intracranial Hemorrhage: A Meta-Analysis and Literature Review , 2023, Neurosurgery.

[5]  A. Stang,et al.  Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study , 2023, International journal of stroke : official journal of the International Stroke Society.

[6]  D. Werring,et al.  Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. , 2023, The New England journal of medicine.

[7]  E. Kristoffersen,et al.  Antithrombotic Treatment, Prehospital Blood Pressure, and Outcomes in Spontaneous Intracerebral Hemorrhage. , 2023, Journal of the American Heart Association.

[8]  Kristine M. Thompson,et al.  Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage , 2022, JAMA network open.

[9]  M. Marietta,et al.  Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review , 2022, Advances in Therapy.

[10]  B. Norrving,et al.  Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study , 2022, Circulation.

[11]  L. Schwamm,et al.  Clinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants , 2022, Journal of Neurology.

[12]  K. Sheth,et al.  Protecting the Brain, From the Heart: Safely Mitigating the Consequences of Thrombosis in Intracerebral Hemorrhage Survivors With Atrial Fibrillation , 2022, Stroke.

[13]  J. Mocco,et al.  2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. , 2022, Stroke.

[14]  D. Shin,et al.  Restarting anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation: A nationwide retrospective cohort study , 2022, International journal of cardiology. Heart & vasculature.

[15]  Sung-Chun Tang,et al.  Post‐Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation , 2022, Journal of the American Heart Association.

[16]  J. van der Naalt,et al.  Mild traumatic brain injury in elderly patients receiving direct oral anticoagulants: A systematic review and meta-analysis. , 2022, Journal of neurotrauma.

[17]  G. Lip,et al.  Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial , 2022, International journal of stroke : official journal of the International Stroke Society.

[18]  G. Lip,et al.  Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation , 2021, Annals of neurology.

[19]  A. Algra,et al.  Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial , 2021, The Lancet Neurology.

[20]  A. Demchuk,et al.  Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care , 2021, Stroke.

[21]  J. Weitz,et al.  Ciraparantag as a potential universal anticoagulant reversal agent. , 2021, European heart journal.

[22]  S. Jiang,et al.  Risk of Intracranial Hemorrhage Caused by Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation (from a Network Meta-Analysis of Randomized Controlled Trials). , 2021, The American journal of cardiology.

[23]  J. Ansell,et al.  Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects , 2021, European heart journal.

[24]  G. Lip,et al.  Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. , 2021, The Lancet. Neurology.

[25]  A. Demchuk,et al.  Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage , 2021, Stroke.

[26]  A. Camm,et al.  2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  Chenyang Lv,et al.  Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials , 2021, Journal of Neurology.

[28]  T. Potpara,et al.  Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[29]  Mariel G Kozberg,et al.  A practical approach to the management of cerebral amyloid angiopathy , 2020, International journal of stroke : official journal of the International Stroke Society.

[30]  J. Ansell,et al.  Ciraparantag, an Anticoagulant Reversal Drug: Mechanism of Action, Pharmacokinetics and Reversal of Anticoagulants. , 2020, Blood.

[31]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[32]  Ruibing Wang,et al.  Heparin reversal by an oligoethylene glycol functionalized guanidinocalixarene , 2020, Chemical science.

[33]  C. Reutelingsperger,et al.  The Anticoagulant and Nonanticoagulant Properties of Heparin , 2020, Thrombosis and Haemostasis.

[34]  K. Mahaffey,et al.  2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[35]  H. Kamel,et al.  Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage , 2020, Stroke.

[36]  W. Ageno,et al.  Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. , 2020, European journal of internal medicine.

[37]  K. Derry,et al.  Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products , 2020, Journal of Thrombosis and Thrombolysis.

[38]  T. Chao,et al.  Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage , 2020, JAMA network open.

[39]  Aman B Patel,et al.  Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages , 2020, Journal of thrombosis and haemostasis : JTH.

[40]  G. Brophy,et al.  Factor Xa Inhibitor-Related Intracranial Hemorrhage , 2020, Circulation.

[41]  H. Kirshner,et al.  Management of Intracerebral Hemorrhage: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.

[42]  A. Sweidan,et al.  Coagulopathy reversal in intracerebral haemorrhage , 2020, Stroke & Vascular Neurology.

[43]  T. Milling,et al.  A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. , 2020, Trends in cardiovascular medicine.

[44]  T. Neumann-Haefelin,et al.  Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases , 2020, International journal of stroke : official journal of the International Stroke Society.

[45]  G. Lip,et al.  Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage , 2019, Stroke.

[46]  D. Werring,et al.  Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use , 2019, Journal of Neurology.

[47]  A. Demchuk,et al.  Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials. , 2019, JAMA neurology.

[48]  P. Bentley,et al.  Prothrombin Complex Concentrates are Superior to Fresh Frozen Plasma for Emergency Reversal of Vitamin K Antagonists: A Meta-Analysis in 2606 Subjects , 2019, Drugs.

[49]  H. Huttner,et al.  Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage , 2019, Critical Care.

[50]  S. Yaghi,et al.  Anticoagulation Resumption After Stroke from Atrial Fibrillation , 2019, Current Atherosclerosis Reports.

[51]  G. Fink,et al.  Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage. , 2019, Stroke.

[52]  G. Lip,et al.  Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage , 2019, Stroke.

[53]  J. Leitgeb,et al.  Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement , 2019, Critical Care.

[54]  A. Demchuk,et al.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors , 2019, The New England journal of medicine.

[55]  A. Sweidan,et al.  Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage , 2019, Stroke.

[56]  S. Schulman,et al.  Treatment of bleeding complications in patients on anticoagulant therapy. , 2019, Blood.

[57]  C. Haynes,et al.  Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. , 2018, Blood advances.

[58]  I. Eyüpoglu,et al.  Initiating anticoagulant therapy after ICH is associated with patient characteristics and treatment recommendations , 2018, Journal of Neurology.

[59]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[60]  J. Leeds,et al.  Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model , 2018, PloS one.

[61]  S. Matsuda,et al.  Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin , 2018, Neurology.

[62]  G. Fink,et al.  Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves , 2018, European heart journal.

[63]  R. Calabró,et al.  Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy) , 2018, Thrombosis and Haemostasis.

[64]  Eric E. Smith,et al.  Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality , 2018, JAMA.

[65]  J. Douketis,et al.  Reversal agents for non-vitamin K antagonist oral anticoagulants , 2018, Nature Reviews Cardiology.

[66]  G. Fink,et al.  Association of prothrombin complex concentrate administration and hematoma enlargement in non–vitamin K antagonist oral anticoagulant–related intracerebral hemorrhage , 2018, Annals of neurology.

[67]  J. Sterne,et al.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, British Medical Journal.

[68]  A. Iorio,et al.  Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. , 2017, Thrombosis research.

[69]  J. Odeberg,et al.  Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. , 2017, Blood.

[70]  P. Heuschmann,et al.  Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation , 2017, Neurology.

[71]  J. Sweeney,et al.  Rapid response to intravenous vitamin K may obviate the need to transfuse prothrombin complex concentrates , 2017, Transfusion.

[72]  J. Jeng,et al.  Outcome of intracerebral hemorrhage associated with different oral anticoagulants , 2017, Neurology.

[73]  M. Gottlieb,et al.  Idarucizumab for the Reversal of Dabigatran. , 2017, Annals of emergency medicine.

[74]  F. Skjøth,et al.  Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation , 2017, JAMA internal medicine.

[75]  S. Johnsen,et al.  Letter by Nielsen and Johnsen Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation". , 2017, Stroke.

[76]  B. Ritchie,et al.  Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. , 2017, Thrombosis research.

[77]  D. Adams.  Idarucizumab for Dabigatran Reversal Full Cohort Analysis , 2017 .

[78]  M. Chung,et al.  Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association , 2017, Circulation.

[79]  K. Asplund,et al.  Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation , 2017, Stroke.

[80]  M. Mercuri,et al.  Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban , 2016, Thrombosis and Haemostasis.

[81]  J. Ansell,et al.  Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. , 2016, Thrombosis research.

[82]  J. Uhm,et al.  Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. , 2016, Heart rhythm.

[83]  T. Bakchoul,et al.  Protamine (heparin)‐induced thrombocytopenia: a review of the serological and clinical features associated with anti‐protamine/heparin antibodies , 2016, Journal of thrombosis and haemostasis : JTH.

[84]  T. Steiner,et al.  Adverse Events Following International Normalized Ratio Reversal in Intracerebral Hemorrhage , 2016, Cerebrovascular Diseases.

[85]  A. Brandes,et al.  Use of Antithrombotic Therapy and Long-Term Clinical Outcome Among Patients Surviving Intracerebral Hemorrhage , 2016, Stroke.

[86]  S. Glund,et al.  Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study , 2016, Clinical Pharmacokinetics.

[87]  W. Hacke,et al.  Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial , 2016, The Lancet Neurology.

[88]  T. Chao,et al.  Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage , 2016, Circulation.

[89]  J. Teitelbaum,et al.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage , 2016, Neurocritical Care.

[90]  S. Middeldorp,et al.  In vivo reversal of the anticoagulant effect of rivaroxaban with four‐factor prothrombin complex concentrate , 2016, British journal of haematology.

[91]  W. Ageno,et al.  Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. , 2015, Thrombosis research.

[92]  S. Middeldorp,et al.  In vivo increase in thrombin generation by four‐factor prothrombin complex concentrate in apixaban‐treated healthy volunteers , 2015, Journal of thrombosis and haemostasis : JTH.

[93]  M. Crowther,et al.  Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review , 2015, Journal of thrombosis and haemostasis : JTH.

[94]  I. López-Vílchez,et al.  Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. , 2015, Transfusion medicine reviews.

[95]  G. Lip,et al.  Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study , 2015, Circulation.

[96]  Bcps,et al.  Idarucizumab for dabigatran reversal , 2015 .

[97]  J. Mega,et al.  Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments , 2015, The Lancet.

[98]  Mario Zuccarello,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[99]  G. Fink,et al.  Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. , 2015, JAMA.

[100]  D. Monroe,et al.  Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate , 2015, Anesthesiology.

[101]  N. Maillard,et al.  Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit , 2015, Clinical kidney journal.

[102]  E. Antman,et al.  Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate , 2015, Circulation.

[103]  C. Haynes,et al.  Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants , 2014, Science Translational Medicine.

[104]  D. Krieger,et al.  European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage , 2014, International journal of stroke : official journal of the International Stroke Society.

[105]  H. Büller,et al.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. , 2014, Blood.

[106]  Manesh R. Patel,et al.  Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers , 2014, Journal of thrombosis and haemostasis : JTH.

[107]  L. Aledort,et al.  Reversal of Coagulopathy Using Prothrombin Complex Concentrates is Associated with Improved Outcome Compared to Fresh Frozen Plasma in Warfarin-Associated Intracranial Hemorrhage , 2014, Neurocritical Care.

[108]  A. Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[109]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[110]  R. Veltkamp,et al.  Intracerebral Bleeding in Patients on Antithrombotic Agents , 2013, Seminars in Thrombosis & Hemostasis.

[111]  R. Hoffman,et al.  Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[112]  J. Goldstein,et al.  Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study , 2013, Circulation.

[113]  E. Irwin,et al.  Therapeutic anticoagulation can be safely accomplished in selected patients with traumatic intracranial hemorrhage , 2012, World Journal of Emergency Surgery.

[114]  K. Butcher,et al.  Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal , 2012, Stroke.

[115]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[116]  W. Ageno,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[117]  M. Samama,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[118]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[119]  M. Makris,et al.  Protamine reversal of low molecular weight heparin: clinically effective? , 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[120]  C. Samama,et al.  Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model , 2010, Thrombosis and Haemostasis.

[121]  B. Skolnick,et al.  Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. , 2010, Blood.

[122]  S. Mayer,et al.  Thromboembolic Events With Recombinant Activated Factor VII in Spontaneous Intracerebral Hemorrhage: Results From the Factor Seven for Acute Hemorrhagic Stroke (FAST) Trial , 2010, Stroke.

[123]  V. Feigin,et al.  Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review , 2009, The Lancet Neurology.

[124]  C. Négrier,et al.  Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. , 2009, Thrombosis research.

[125]  J. Broderick,et al.  Warfarin use leads to larger intracerebral hematomas , 2008, Neurology.

[126]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.

[127]  P. Johansen,et al.  Recombinant human factor VIIa and a factor VIIa‐analogue reduces heparin and low molecular weight heparin (LMWH)‐induced bleeding in rats , 2008, Journal of thrombosis and haemostasis : JTH.

[128]  G. Young,et al.  Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[129]  W. Ageno,et al.  Prothrombin Complex Concentrates for Urgent Anticoagulation Reversal in Patients with Intracranial Haemorrhage , 2007, Pathophysiology of Haemostasis and Thrombosis.

[130]  J. Stassen,et al.  In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate , 2007, Thrombosis and Haemostasis.

[131]  J. Broderick,et al.  The increasing incidence of anticoagulant-associated intracerebral hemorrhage , 2007, Neurology.

[132]  R. MacLaren,et al.  A multicenter assessment of recombinant factor VIIa off‐label usage: clinical experiences and associated outcomes , 2005, Transfusion.

[133]  P. D. de Groot,et al.  Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux , 2003, Journal of thrombosis and haemostasis : JTH.

[134]  V. Marder,et al.  Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin , 2003, Journal of thrombosis and haemostasis : JTH.

[135]  R. Peters,et al.  Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers , 2002, Circulation.

[136]  A. J. Roberts,et al.  Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. , 2019, Thrombosis research.

[137]  G. Lip,et al.  Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis , 2017, Stroke.

[138]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[139]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[140]  S. Schulman,et al.  Anticoagulants and their reversal. , 2007, Transfusion medicine reviews.

[141]  J Ingerslev,et al.  Use of recombinant factor VIIa for emergency reversal of anticoagulation. , 2007, Journal of postgraduate medicine.

[142]  J. Broderick,et al.  Location and outcome of anticoagulant-associated intracerebral hemorrhage , 2006, Neurocritical care.